Human herpesvirus-6 (HHV-6), the Roseolovirus genus of the bherpesvirus subfamily, is latent not only in CD4 þ T cells but also in the brain. 1, 2 Although reactivation of HHV-6 in the peripheral blood has been reported to occur frequently in patients who have undergone allogeneic stem cell transplantation, 3 encephalitis due to HHV-6 rarely develops. Among 338 recipients of bone marrow transplant, the incidence of central nervous system (CNS) symptoms associated with HHV-6 in the cerebrospinal fluid (CSF) was only 1.5% (five patients). 4 Recipients grafted with stem cells from HLA-mismatched donors have an increased risk of HHV-6 reactivation and disease, 4, 5 which is also implicated as a cause of the initiation and exacerbation of graft-versus-host disease (GVHD). Here, we describe a patient who developed life-threatening acute GVHD following HHV-6 encephalitis after allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-haploidentical sibling mismatched for noninherited maternal HLA antigens (NIMA).
A 35-year-old man with refractory acute myeloid leukemia (FAB classification, M4e) received an allogeneic PBSCT from his HLA-haploidentical NIMA-complementary sister. Maternal-specific HLA alleles were detected in DNA samples from peripheral blood of the patient and his sister using the reported methods, [6] [7] [8] suggesting that both had immunological tolerance to NIMA. Pretransplant conditioning consisted of cyclophosphamide (120 mg/kg) and total body irradiation (12 Gy in 6 fractions). Peripheral blood stem cells (2.03 Â 10 6 CD34 cells/kg) mobilized by granulocyte colony-stimulating factor and collected by apheresis were infused on the day of transplantation (day 0) without T-cell depletion. For GVHD prophylaxis, the patient received a continuous infusion of tacrolimus at 0.02 mg/kg combined with intravenous methotrexate at 10 mg/m 2 on day 1, and at 7 mg/m 2 on days 3 and 6. Methylprednisolone was administered for persisting fever on day 11, which improved his general condition. However, on day 17, the patient exhibited stupor, disorientation, and amnesia for recent event. He then developed systemic convulsions and became comatose. Irregular respiration and oligopnea with hypercapnia developed, for which mechanical ventilation was required. Computed tomography and magnetic resonance imaging of the brain showed nonspecific findings. Owing tothe characteristic symptoms of loss of short-term memory, disorientation, confusion, seizure, and coma early after transplantation, HHV-6 encephalitis was suspected, and ganciclovir was started from day 17. To exclude the possibility of tacrolimus-induced encephalopathy, this was discontinued on day 17, and restarted on day 18 at lower blood levels. HHV-6 DNA (variant B) was detected from CSF and plasma at levels of 8 Â 10 4 and 1 Â 10 3 copies/ml, respectively, by quantitative PCR on day 18 (Figure 1 ), confirming the diagnosis of HHV-6 encephalitis. HSV, cytomegalovirus (CMV), and varicella zoster virus were not detected in the CSF. No bacteria or fungi were isolated from the CSF. The number of neutrophils exceeded 500/ml on day 16. Palmar erythema developed on day 20, histologically compatible with acute GVHD. A generalized skin rash occurred on day 22, despite treatment with methylprednisolone, accompanied by torrential. Colonoscopy on day 27 showed pronounced swelling of erythematous mucosa. Finally, the volume of diarrhea increased to up to 8 l/day. High-dose methylprednisolone and mycophenolate mofetil (MMF) were instituted, but ineffective. To control the acute GVHD, infliximab at a dose of 10 mg/kg was administered on day 29, with temporary improvement. Ganciclovir was administered for 2 weeks for the treatment of HHV-6 encephalitis, and was then restarted for CMV antigenemia from day 42. Colonoscopy on day 48 showed diffuse mucosal ulceration without CMV inclusion bodies and the diagnosis of intestinal GVHD was made. Treatment with tacrolimus, corticosteroids, MMF, and ganciclovir was continued. The diarrhea was considered to be a manifestation of acute GVHD because the volume of diarrhea started to increase before the administration of MMF, and gradually regressed while MMF was continued over 10 weeks. His mental status gradually recovered, but he still had disturbances of short-term memory. Quantitative PCR of the bone marrow for CBFB/ MYH11 on day 140 revealed that he was in complete remission from his leukemia at the molecular level.
This patient showed the clinical characteristics of HHV-6 encephalitis, in terms of time of onset, symptoms such as loss of short-term memory, and clinical response to ganciclovir, as recently described. 9 It is of interest to note that severe acute GVHD developed following HHV-6 encephalitis. HHV-6 DNA is detected more frequently in patients with acute GVHD than in those without GVHD. 3, 5 In our patient, HHV-6 encephalitis preceded the occurrence of severe acute GVHD. Moreover, severe acute GVHD was not reported in four patients receiving stem-cell grafts from NIMAcomplementary sibling donors. [7] [8] 10 A temporal relationship between HHV-6 infection and severe acute GVHD in our patient suggests that acute GVHD could be triggered by HHV-6 infection after allogeneic stem cell transplantation. As for CMV infection, the elevated interferon gamma enhances expression of the major histocompatibility class I and class II antigens, giving rise to activation of alloreactive donor T cells, and thus inducing acute GVHD. 11 It is possible that a similar mechanism may function in HHV-6 infection. Exacerbation of GVHD following the development of herpes zoster has also been reported after allogeneic stem cell transplantation. 12 There were 14 fatalities in patients developing HHV-6 encephalitis, among which five patients died of acute GVHD. 2, 9, 10, [13] [14] [15] [16] Although the direct association between HHV-6 infection and acute GVHD cannot be proven on the basis of a single case report, our experience suggests that careful management of acute GVHD against HHV-6 encephalitis and any subsequent GVHD may be important in the setting of non-T-celldepleted stem cell transplantation from an HLA-haploidentical NIMA-mismatched family member, even if long-term feto-maternal microchimerism is detected in the donor. 
